Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis

NCT ID: NCT06566638

Last Updated: 2025-03-20

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-01
• Study Completion Date: 2027-04-01

Brief Summary

This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.

Detailed Description

This study investigates the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in patients with acute pancreatitis. Acute pancreatitis is one of the leading gastrointestinal disorders that require urgent clinical care and is increasing in incidence.

cfDNA/NET therapeutic apheresis with NucleoCapture is indicated for the treatment of diseases in which excessive levels of cfDNA/NETs are found, such as acute pancreatitis. Participants will be randomised to receive either standard of care (SOC) alone or SOC plus NucleoCapture treatment. SOC will be according to the current guidelines described by the European Society of Intensive Medicine (ESICM). Participants in the SOC plus NucleoCapture arm will receive one treatment session with NucleoCapture per day, for the first three days. Each treatment session with NucleoCapture will last for up 6 hours, aiming to treat 4.5 plasma volumes. Treatment sessions with NucleoCapture treating less than 3.5 plasma volumes will be counted as incomplete and the treatment session will be repeated on the following day, up to day 5 maximum.

Assessments will take place for all participants whilst in the Intensive Care Unit (ICU) on days 1 to 5, 7, 14, 21 and 28, and at 90 days post discharge to ward-based care. Participants transferred to ward-based care before day 28 will receive no further study assessment visits from the point of transfer to ward-based care, apart from day 28 in which participants will receive a final study assessment visit and a patient reported outcome assessment (PROM) 90 days post discharge to ward-based care.

Conditions

Acute Pancreatitis; Organ Failure, Multiple

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SOC plus NucleoCapture

Participants in the treatment arm will receive SOC plus three apheresis treatment sessions with the NucleoCapture device. The device consists of 100ml NucleoCapture selective adsorber.

Group Type: EXPERIMENTAL

NucleoCapture device

Intervention Type: DEVICE

100ml NucleoCapture selective DNA adsorber.

SOC

Participants in the SOC arm will receive SOC alone, in accordance with ESICM guidelines.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

NucleoCapture device

100ml NucleoCapture selective DNA adsorber.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Adult patients aged 18 or over

2. Acute pancreatitis (following revised Atlanta definition of 2 out of typical pain, serum amylase >3x normal range and/or CT/MRI imaging consistent with pancreatitis)

3. Any aetiology

4. Acute respiratory (PaO2/FiO2 <300), cardiovascular (systolic BP <90 or any inotropic therapy) or renal failure (serum creatinine >170 µmol/l, or deterioration of >50% eGFR if pre-existing renal disease or urine output <0.5ml/kg/hr for 3 consecutive hours) presenting at any point during the index admission and persistent after 12 h of fluid resuscitation, but for not more than 72 hours

5. Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law).

Exclusion Criteria

6. The use of other non-routine extracorporeal treatments such as very high flux renal replacement therapy (>60ml/kg/h total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc).

7. Presence of severe multiple organ failure at the point of enrolment as evidenced by:

• Severe refractory vasoplegic failure

• Norepinephrine dose > 0.60 μg/kg/min
• Use of epinephrine
• Concomitant cardiogenic shock, clinically suspected or cardiac index <2.2 L/min/m2 if measured

• Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan
• Coagulopathy as defined by Platelet count <50x10^9/L

8. Calculated Plasma Volume greater than 5000ml as determined by the following formula:

Vplasma = Vblood x (1 - haematocrit)

Where:

Vplasma = PV Vblood = an estimation of total blood volume (TBV; according to Nadler's formula, incorporating height, weight and sex).

A TBV calculator is available at https://www.omnicalculator.com/health/blood-volume

9. Known liver cirrhosis (histologically proven or clinically suspected)

10. Active bleeding

11. Known citrate intolerance if citrate is required for therapeutic apheresis

12. Known heparin allergy if heparin is required for therapeutic apheresis

13. Known metastatic disease with life expectancy of <12 months and ECOG score of at least 2

14. Known haematological malignancy if not in remission

15. Known solid organ transplant and concomitant use of immunosuppression

16. Known long term oxygen therapy or Home oxygen use

17. Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)

18. Planned or impending dialysis

19. Prior use of cardiopulmonary resuscitation (CPR) in current admission

20. Requirement for extracorporeal membrane oxygenation (ECMO)

21. Patient expected to die within 48 hours of admission to ICU

22. Known allergy to components of NucleoCapture (Sepharose beads and linker histone H1.3)

23. Pre-existing disease of the exocrine pancreas including chronic pancreatitis, recurrent acute pancreatitis, pancreatic malignancy and/or history of pancreatic surgery

24. Chronic neuromuscular disease affected breathing

25. Current Participation in another interventional clinical study

26. Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Santersus AG

INDUSTRY

Sponsor Role: collaborator

Liverpool University Hospitals NHS Foundation Trust

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter Szatmary

Role: PRINCIPAL_INVESTIGATOR

Liverpool University Hospitals NHS Foundation Trust

Locations

Liverpool University Hospitals NHS Foundation Trust

Liverpool, , United Kingdom

Countries

United Kingdom

Central Contacts

Heather Rogers

Role: CONTACT

Heather.Rogers@liverpoolft.nhs.uk

+44 151 706 3702

Facility Contacts

Peter Szatmary

Role: primary

Peter.Szatmary@liverpoolft.nhs.uk

Other Identifiers

LHS0096

Identifier Type: -

Identifier Source: org_study_id